Stein Steven H
Incyte Corporation · CMO & Head of Late-Stage Dev.
Stein Steven H serves as the Chief Medical Officer and Head of Late-Stage Development at Incyte Corporation, a biopharmaceutical company focused on innovative cancer therapies. His recent trading activity, tracked through SEC Form 4 filings, highlights a pattern of sale activity with reported amounts ranging from $254.4K to $1.6M between January 2025 and July 2026. Notably, his largest disclosed move involved a grant/exercise valued at approximately $2.1 million on January 21, 2026, underscoring his active role in the company's financial landscape.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $3M28.2k shares | SellJul 15, 2026 | $113.05 | $115.09 | |
| $898k12.4k shares | SellJan 21, 2025 | $72.69 | $115.09 | |
| $1M15k shares | SellJul 14, 2025 | $68.47 | $115.09 | |
| $252k3.7k shares | SellJul 21, 2025 | $67.94 | $115.09 | |
| $535k5.2k shares | SellNov 5, 2025 | $102.20 | $115.09 | |
| $2M20.1k shares | SellDec 2, 2025 | $102.51 | $115.09 | |
| $263k2.6k shares | SellDec 1, 2025 | $102.96 | $115.09 | |
| $2M15.6k shares | SellJan 5, 2026 | $101.70 | $115.09 |